ePrints
Items where Author is "Wan, X"
 | Up a level |
Group by: Item Type | No Grouping
Number of items: 5.
Article
Liu, Q, Luo, X, Zhou, Z 
ORCID: 0000-0002-0835-8686, Peng, L, Yi, L, Wan, X, Tan, C and Zeng, X 2021
, 'PD-L1 test-based strategy with Nivolumab as the second-line treatment in advanced NSCLC: A cost-effectiveness analysis in China'
, Frontiers in Oncology, vol. 11
, pp. 1-11
, doi: https://doi.org/10.3389/fonc.2021.745493.
ORCID: 0000-0002-0835-8686, Peng, L, Yi, L, Wan, X, Tan, C and Zeng, X 2021
, 'PD-L1 test-based strategy with Nivolumab as the second-line treatment in advanced NSCLC: A cost-effectiveness analysis in China'
, Frontiers in Oncology, vol. 11
, pp. 1-11
, doi: https://doi.org/10.3389/fonc.2021.745493.
Liu, Q, Zhou, Z ORCID: 0000-0002-0835-8686, Luo, X, Yi, L, Peng, L, Wan, X, Tan, C and Zeng, X 2022
, 'Cost-effectiveness of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy in metastatic non-squamous and squamous NSCLC patients With PD-L1 expression ≥ 50%'
, Frontiers in Pharmacology, vol. 12
, pp. 1-10
, doi: https://doi.org/10.3389/fphar.2021.803626.
ORCID: 0000-0002-0835-8686, Luo, X, Yi, L, Peng, L, Wan, X, Tan, C and Zeng, X 2022
, 'Cost-effectiveness of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy in metastatic non-squamous and squamous NSCLC patients With PD-L1 expression ≥ 50%'
, Frontiers in Pharmacology, vol. 12
, pp. 1-10
, doi: https://doi.org/10.3389/fphar.2021.803626.
Liu, Q, Zhou, Z ORCID: 0000-0002-0835-8686, Luo, X, Yi, L, Peng, L, Wan, X, Tan, C and Zeng, X 2021
, 'First-line ICI monotherapies for advanced non-small-cell lung cancer patients with PD-L1 of at least 50%: A cost-effectiveness analysis'
, Frontiers in Pharmacology, vol. 12
, pp. 1-10
, doi: https://doi.org/10.3389/fphar.2021.788569.
ORCID: 0000-0002-0835-8686, Luo, X, Yi, L, Peng, L, Wan, X, Tan, C and Zeng, X 2021
, 'First-line ICI monotherapies for advanced non-small-cell lung cancer patients with PD-L1 of at least 50%: A cost-effectiveness analysis'
, Frontiers in Pharmacology, vol. 12
, pp. 1-10
, doi: https://doi.org/10.3389/fphar.2021.788569.
Liu, Q, Zhou, Z ORCID: 0000-0002-0835-8686, Luo, X, Yi, L, Peng, L, Wan, X, Tan, C and Zeng, X 2021
, 'First-line ICI monotherapies for advanced non-small-cell lung cancer patients with PD-L1 of at least 50%: A cost-effectiveness analysis'
, Frontiers in Pharmacology, vol. 12
, pp. 1-10
, doi: https://doi.org/10.3389/fphar.2021.788569.
ORCID: 0000-0002-0835-8686, Luo, X, Yi, L, Peng, L, Wan, X, Tan, C and Zeng, X 2021
, 'First-line ICI monotherapies for advanced non-small-cell lung cancer patients with PD-L1 of at least 50%: A cost-effectiveness analysis'
, Frontiers in Pharmacology, vol. 12
, pp. 1-10
, doi: https://doi.org/10.3389/fphar.2021.788569.
Luo, X, Liu, Q, Zhou, Z ORCID: 0000-0002-0835-8686, Yi, L, Peng, L, Wan, X, Zeng, X, Tan, C and Li, S 2022
, 'Cost-effectiveness of Bevacizumab Biosimilar LY01008 combined with chemotherapy as first-line treatment for chinese patients with advanced or recurrent nonsquamous non-small cell lung cancer'
, Frontiers in Pharmacology, vol. 13
, doi: https://doi.org/10.3389/fphar.2022.832215.
ORCID: 0000-0002-0835-8686, Yi, L, Peng, L, Wan, X, Zeng, X, Tan, C and Li, S 2022
, 'Cost-effectiveness of Bevacizumab Biosimilar LY01008 combined with chemotherapy as first-line treatment for chinese patients with advanced or recurrent nonsquamous non-small cell lung cancer'
, Frontiers in Pharmacology, vol. 13
, doi: https://doi.org/10.3389/fphar.2022.832215.